JP2022514823A5 - - Google Patents
Info
- Publication number
- JP2022514823A5 JP2022514823A5 JP2021531964A JP2021531964A JP2022514823A5 JP 2022514823 A5 JP2022514823 A5 JP 2022514823A5 JP 2021531964 A JP2021531964 A JP 2021531964A JP 2021531964 A JP2021531964 A JP 2021531964A JP 2022514823 A5 JP2022514823 A5 JP 2022514823A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062686A JP2024095769A (ja) | 2018-12-06 | 2024-04-09 | アセチル－ロイシンの重水素化類似体 |
| JP2025178241A JP2026016521A (ja) | 2018-12-06 | 2025-10-23 | アセチル－ロイシンの重水素化類似体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776297P | 2018-12-06 | 2018-12-06 | |
| US62/776,297 | 2018-12-06 | ||
| PCT/IB2019/060525 WO2020115715A1 (en) | 2018-12-06 | 2019-12-06 | Deuterated analogs of acetyl-leucine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062686A Division JP2024095769A (ja) | 2018-12-06 | 2024-04-09 | アセチル－ロイシンの重水素化類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514823A JP2022514823A (ja) | 2022-02-16 |
| JP2022514823A5 true JP2022514823A5 (enExample) | 2022-12-15 |
| JP7471298B2 JP7471298B2 (ja) | 2024-04-19 |
Family
ID=68887086
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531964A Active JP7471298B2 (ja) | 2018-12-06 | 2019-12-06 | アセチル－ロイシンの重水素化類似体 |
| JP2024062686A Withdrawn JP2024095769A (ja) | 2018-12-06 | 2024-04-09 | アセチル－ロイシンの重水素化類似体 |
| JP2025178241A Pending JP2026016521A (ja) | 2018-12-06 | 2025-10-23 | アセチル－ロイシンの重水素化類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062686A Withdrawn JP2024095769A (ja) | 2018-12-06 | 2024-04-09 | アセチル－ロイシンの重水素化類似体 |
| JP2025178241A Pending JP2026016521A (ja) | 2018-12-06 | 2025-10-23 | アセチル－ロイシンの重水素化類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12145899B2 (enExample) |
| EP (1) | EP3886986A1 (enExample) |
| JP (3) | JP7471298B2 (enExample) |
| KR (2) | KR102765448B1 (enExample) |
| CN (2) | CN113348018B (enExample) |
| AU (1) | AU2019391434B2 (enExample) |
| BR (1) | BR112021010923A2 (enExample) |
| IL (2) | IL319687A (enExample) |
| MA (1) | MA54289A (enExample) |
| MX (2) | MX2021006559A (enExample) |
| SA (1) | SA521422185B1 (enExample) |
| SG (1) | SG11202106009TA (enExample) |
| WO (1) | WO2020115715A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US20120101168A1 (en) * | 2010-10-26 | 2012-04-26 | Eliezer Bahar | Deuterium enriched rasagiline |
| ES2901752T3 (es) | 2013-02-05 | 2022-03-23 | Teva Pharmaceuticals Int Gmbh | Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| DK3359146T3 (en) * | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| HUE062729T2 (hu) | 2017-03-28 | 2023-12-28 | Intrabio Ltd | Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| MA51836B1 (fr) | 2018-02-15 | 2025-01-31 | Intrabio Ltd | Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| US10950670B2 (en) * | 2018-12-17 | 2021-03-16 | Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. | Display panel |
| SMT202400334T1 (it) * | 2019-03-02 | 2024-09-16 | Intrabio Ltd | (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche |
| RS67283B1 (sr) | 2019-06-28 | 2025-11-28 | Intrabio Ltd | Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja |
| WO2021144720A1 (en) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| US20230201150A1 (en) * | 2020-05-22 | 2023-06-29 | Intrabio Ltd. | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
-
2019
- 2019-12-06 EP EP19820881.1A patent/EP3886986A1/en active Pending
- 2019-12-06 AU AU2019391434A patent/AU2019391434B2/en active Active
- 2019-12-06 SG SG11202106009TA patent/SG11202106009TA/en unknown
- 2019-12-06 WO PCT/IB2019/060525 patent/WO2020115715A1/en not_active Ceased
- 2019-12-06 MX MX2021006559A patent/MX2021006559A/es unknown
- 2019-12-06 CN CN201980090399.8A patent/CN113348018B/zh active Active
- 2019-12-06 MA MA054289A patent/MA54289A/fr unknown
- 2019-12-06 CN CN202510303881.2A patent/CN120157593A/zh active Pending
- 2019-12-06 BR BR112021010923-4A patent/BR112021010923A2/pt unknown
- 2019-12-06 IL IL319687A patent/IL319687A/en unknown
- 2019-12-06 JP JP2021531964A patent/JP7471298B2/ja active Active
- 2019-12-06 KR KR1020217019782A patent/KR102765448B1/ko active Active
- 2019-12-06 IL IL283673A patent/IL283673B2/en unknown
- 2019-12-06 KR KR1020257003486A patent/KR20250022899A/ko active Pending
- 2019-12-06 US US17/311,240 patent/US12145899B2/en active Active
-
2021
- 2021-06-03 MX MX2024005670A patent/MX2024005670A/es unknown
- 2021-06-06 SA SA521422185A patent/SA521422185B1/ar unknown
-
2024
- 2024-04-09 JP JP2024062686A patent/JP2024095769A/ja not_active Withdrawn
- 2024-10-21 US US18/921,779 patent/US20250129011A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178241A patent/JP2026016521A/ja active Pending